CN1092072A - 药用组合物 - Google Patents
药用组合物 Download PDFInfo
- Publication number
- CN1092072A CN1092072A CN93115028A CN93115028A CN1092072A CN 1092072 A CN1092072 A CN 1092072A CN 93115028 A CN93115028 A CN 93115028A CN 93115028 A CN93115028 A CN 93115028A CN 1092072 A CN1092072 A CN 1092072A
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- formula
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- -1 benzimidazolyl- Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 16
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 16
- 150000000531 4H-pyrans Chemical class 0.000 description 13
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 12
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000003053 piperidines Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 0 CC(C1*)C(*)OC2=C1C=CC1C=CC=NC21 Chemical compound CC(C1*)C(*)OC2=C1C=CC1C=CC=NC21 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229940095102 methyl benzoate Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IAGXCFRBKLIQIR-UHFFFAOYSA-N 2-[[3-(trifluoromethyl)phenyl]methylidene]propanedinitrile Chemical compound FC(F)(F)C1=CC=CC(C=C(C#N)C#N)=C1 IAGXCFRBKLIQIR-UHFFFAOYSA-N 0.000 description 2
- WAVNYPVYNSIHNC-UHFFFAOYSA-N 2-benzylidenepropanedinitrile Chemical compound N#CC(C#N)=CC1=CC=CC=C1 WAVNYPVYNSIHNC-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000675108 Citrus tangerina Species 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 1
- UQMJZLGIKHAOQZ-UHFFFAOYSA-N 2-[(3-nitrophenyl)methylidene]propanedinitrile Chemical compound [O-][N+](=O)C1=CC=CC(C=C(C#N)C#N)=C1 UQMJZLGIKHAOQZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000254171 Curculionidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical compound N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- CSNXUYRHPXGSJD-UHFFFAOYSA-N isoquinolin-5-ol Chemical compound N1=CC=C2C(O)=CC=CC2=C1 CSNXUYRHPXGSJD-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- DHPJWXFIDZDMHC-UHFFFAOYSA-N methyl 3-(2,2-dicyanoethenyl)benzoate Chemical compound COC(=O)C1=CC=CC(C=C(C#N)C#N)=C1 DHPJWXFIDZDMHC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 150000004880 oxines Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- GYESAYHWISMZOK-UHFFFAOYSA-N quinolin-5-ol Chemical compound C1=CC=C2C(O)=CC=CC2=N1 GYESAYHWISMZOK-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了式(I)化合物的制备方法和药学用
途，式(I)化合物结构中各取代基定义见说明书。
Description
本发明涉及药用化合物及其制备和用途。
先有技术公开了某些吡喃并喹啉，例如下述文献所述的4H-吡喃并[3，2-h]喹啉：
Z.H.Khalil et al.Bull.Chem.Soc.Jpn.，64，668-670（1991），A.G.A.Elagamey et al.Collection Czechoslovak Chem.Commun.，53（7），1534-8（1988），F.M.A.El-Taweel et al.Pharmazie，45（9），671-3（1990），and K.D.Paull et al.Cancer Res.，52（14），3892-3900（1992）.
我们发现，下述通式的化合物及其盐可用作药物：
R1是苯基或选自噻吩基、吡啶基、苯并噻吩基、喹啉基、苯并呋喃基或苯并咪唑基的杂芳基，所述苯基或杂芳基可带有取代基;或者R1是可被C1-4烷基取代的呋喃基;
R2是氰基、羧基、-COOR4（其中R4是酯基）、-CONR5R6（其中R5和R6各自是氢或C1-4烷基）或R7SO2-（其中R7是C1-4烷基或可被取代的苯基），
R3是-NR8R9，-NHCOR8，-N（COR8）2，-N＝CHOR8（其中R8和R9各自是氢或C1-4烷基）或-NHSO2R10（其中R10是C1-4烷基或可被取代的苯基）;或
式中X是C2-4亚烷基;基团
代表与苯并吡喃核稠合的吡啶环。
我们发现，本发明化合物在治疗过度细胞增生或酶释放起主要作
用的免疫性疾病的试验中具有活性，显示出其治疗效能。
上述式（Ⅰ）化合物是新化合物，但如下定义的式（Ⅰ）化合物除外：其中
并且
（ⅰ）R′是苯基或在对位上被一个氯、羟基或甲氧基基团取代的苯基，R2是氰基，且R3是-NH2，
（ⅱ）R′是苯基或在对位上被一个氯、羟基或甲氧基基团取代的苯基，R2是COOC2H5，且R3是-NH2，或者
（ⅲ）R′是苯基，R2是氰基，且R3是-NHCOCH3或-N＝CHOC2H5。
排除在新化合物之外的具体化合物的一个例子是2-氨基-4-苯基-4H-吡喃并[3，2-h]喹啉-3-甲腈。
应当明白，本发明化合物可以下述四种形式存在：
优选的化合物是用结构式（Ⅱ）、（Ⅲ）和（Ⅳ）表示的化合物，特别优选式（Ⅱ）和（Ⅳ）表示的化合物。结构式（Ⅱ）表示的新化合物中有某些化合物不属于新化合物，详见上文。
在上述式（Ⅰ）中，C1-4烷基包括例如：甲基、乙基、丙基和丁基，优选甲基或乙基。
取代的苯基基团是被一个或多个、最好是一个或两个取代基取代的苯基，所述取代基选自例如：卤素、三氟甲基、C1-4烷氧基、羟基、硝基、C1-4烷基、C1-4烷硫基、羟基-C1-4烷基、羟基-C1-4烷氧基、三氟甲氧基、羧基、COOR11（R11是酯基）、-CONR12R13或-NR12R13（其中R12和R13各自是羟基或C1-4烷基）。当取代基为-COOR11时，R11可以是例如芳基-CH2-，如苄基，最好是C1-4烷基，尤其是甲基或乙基。取代的萘基和杂芳基可类似地被取代。此外，取代的苯基包括相邻原子被-O（CH2）mO-（其中m是1，2或3）取代的苯基。
当R′是杂芳基时，它最好是α-噻吩基、3-噻吩基、2-吡啶基、3-吡啶基、4-吡啶基、2-苯并噻吩基、3-苯并噻吩基、2-喹
啉基、3-喹啉基、2-苯并呋喃基、3-苯并呋喃基、2-苯并咪唑基、2-呋喃基或3-呋喃基。在1位或2位上连有萘基基团。所述基团可在任何空位上被取代，但最好是不被取代。
优选的R′是苯基或取代的苯基，最好是被单个取代基取代的苯基，尤其是被硝基、三氟甲基、C1-4烷氧基、特别是甲氧基取代的苯基。或者是被-COOR11取代的苯基，其中R11是C1-4烷基，特别是甲基。一组优选的化合物是其中R1是在间位上被一个取代基取代的苯基的化合物，所述取代基是任何上述的就苯基取代基所列的取代基。
基团R2最好是氰基。当R2是-COOR4时，R4可以是任何酯基，例如：芳基-CH2-如苄基，最好是C1-4烷基，尤其是甲基或乙基。
基团R3最好是-NR8R9，尤其是-NH2。
优选的化合物是那些R1是可被取代的苯基、R2是氰基并且R3是-NH2的化合物。
一组优选的上述式Ⅱ化合物是其中R′是在间位上被一个取代基取代的苯基，R2是氰基并且R3是-NH2。
还有一组优选的式Ⅱ化合物，其中R1是被硝基、三氟甲基、甲氧基或-CO2Me取代的苯基，R2是氰基并且R3是-NH2。
应当理解，例如当R2是-COOH时，有可能形成盐。它们可自任何公知的碱衍生物而来。碱盐的例子是那些从氢氧化铵和碱金属氢氧化物和碱土金属氢氧化物、碳酸盐和碳酸氢盐衍生物而来的盐，以及从脂肪胺和芳香胺、脂肪二胺和羟烷基二胺衍生而来的盐。在制备上述盐时特别有用的碱包括氢氧化铵、碳酸钾、碳酸氢钠、氢氧化锂、氢氧化钙、甲胺、二乙胺、乙二胺、环己胺和乙醇胺。特别优选钾盐、钠盐和锂盐的形式。
应当明白，吡啶核还提供了制备酸加成盐的机会。酸加成盐可由适当的酸制得，例如：无机酸如盐酸、氢溴酸、硝酸、硫酸或磷酸，
或有机酸如有机羧酸象乙醇马来酸、富马酸、马来酸、酒石酸、柠檬酸、水杨酸或邻乙酰氧基苯甲酸，或有机磺酸象甲磺酸、2-羟基乙磺酸、对甲苯磺酸或萘二磺酸。
除药学上可接受的盐之外，本发明还包括其它盐。它们可用作化合物纯化中的中间产物，或可用来制备其它如药学上可接受的酸加成盐，或者可用于鉴定、表征或纯化。
应当明白，本发明化合物含有能产生对映体的不对称碳原子。制备的化合物通常是外消旋体，可方便地直接使用，但如果需要，亦可用常规技术分离出单独的对映体。上述外消旋体和单独的对映体构成了本发明的一部分。
本发明还包括上述式（Ⅰ）化合物的制备方法，它包括：
（1）将式（Ⅵ）化合物
反应，得到R3是-NH2的式（Ⅰ）化合物;或者
（2）将式（Ⅷ）化合物
转化为R3是-NR8R9，NHCOR8，-N（COR8）2，-N＝CHOR8，-NHSO2R10或
的式（Ⅰ）化合物。
作为方法之一的（1），该反应最好于0-100℃并且在有机溶剂（例如乙醇）存在下进行。式（Ⅵ）化合物是已知的或可按已知方法容易地合成。
式（Ⅶ）反应物可通过使适当的腈R2CH2CN与醛R′CHO反应而制
得。反应最好于20-100℃并且在有机碱（例如哌啶）催化剂和有机溶剂（例如乙醇）存在下进行。反应物腈和醛是已知的化合物或是可按本领域公知的方法制备的化合物。
至于方法（2），游离烯胺可通过反应（1）制得，随后转化为R取其它值的化合物。例如：游离氨基可用式R8X或R9X（X＝卤素）的反应物烷基化，得到一或二烷基化的产物。类似地，氨基也可用式R8COX或（R8CO）2O酰化剂酰化，得到R3是-NHCOR8或-N（COR8）2的化合物。R3是-N＝CHOR8的化合物通过与适当的原甲酸三烷酯反应制得，R3是-NHSO2R10的化合物通过与磺酰氨R10SO2X反应制得。
如上所述，该化合物具有药学活性。它们对于细胞类具有抗增生效应，从而表明可用来治疗过度细胞增生或酶释放是主要病源的疾病。
例如，本发明化合物抑制3T3纤维细胞的自然增生，其IC50浓度低于10μM。
此外，该化合物在P.Lacombe等人所述的试验（FEBS，3048，191，227-230）中通过抑制伴刀豆球蛋白A引起的T细胞增生而显示出对免疫应答的改善。
该化合物还抑制NS-1鼠B-淋巴瘤系的细胞增生和佛波醇酯激发的血浆酶原活化剂在牛视网膜毛细内皮细胞中的合成。
在K.Deshmukh-Phadke，M.Lawrence和S.Nanda所述的试验（Biochem.Biophys.Res.Commun.，1978，85，pp.490-496）中还观察到对巨噬细胞调节的中介物质引起的中性蛋白酶释放的抑制作用。
这些性质表明，本发明化合物能有效地治疗很宽范围的疾病，例如：类风湿性关节炎、动脉粥样硬化、肝硬变和癌症;并可用来治疗自动免疫疾病，例如：治疗全身性狼疮;和用来预防移植物排斥。它们也适用于骨关节炎和糖尿病并发症。
此外，本发明化合物显示出对血管平滑肌细胞增生的抑制作用，这点已通过使用取自兔子主动脉的、经培养的平滑细胞而证实，增生的测定是测定DNA的合成。细胞是按照Ross所述的移出方法（J.of Cell Bio.50：172（1971））获得的。将细胞置于96穴微量滴定板上5天时间。培养物融合并停止生长。然后将细胞转移到Dulbecco′s改性Eagle′s培养基（DMEM）中，该培养基含0.5-2%贫血小板血浆、2mM L-谷氨酰胺、100U/ml素霉素、100μg/ml链霉素、1μC/ml3H-胸苷、20ng/ml血小板衍生的生长因子和不同浓度的化合物。化合物的常备溶液在二甲亚砜中制备，然后在上述评定介质中稀释至适当浓度（0.01-10μg/ml）。然后于37℃在5%CO2/95%空气的条件下将细胞培养24小时。24小时后，在甲醇中将细胞固定。混入DNA的3H-胸苷随后用闪烁计数器测定，测定方法参见Bonin等人，Exp.Cell Res.181：475-482（1989）。
本发明化合物对平滑肌细胞的抑制还可通过测定其对指数生长细胞的效应而证实。将取自兔子主动脉的平滑肌细胞置于12穴组织培养板上在DMEM中接种。该DMEM中含有10%胎牛血清、2mM L-谷氨酰胺、100μ/ml青霉素和100μg/ml链霉素。24小时后，将细胞附好，将培养基换成含2%贫血小板血浆、2mM L-谷氨酰胺、100μ/ml青霉素、100μg/ml链霉素、40ng/ml血小板衍生的生长因子和指定浓度化合物的DMEM。让细胞生长4天，用胰蛋白酶处理细胞各培养物的细胞数用ZM-Coulter计数器进行计数测定。
上述试验中的活性表明，本发明化合物能有效地治疗再狭窄，其特征为由外伤引起的平滑肌的胞迁移和增生。
因此，本发明还包括一种药用组合物，该组合物中含有药学上可接受的稀释剂或载体以及式（Ⅰ）化合物或其药学上可接受的盐。
该化合物可以多种途径给药，例如：口服或直肠给药，局部或肠
道外给药例如注射，通常以药用组合物的形式使用。所述组合物构成了本发明的一部分，可按制药行业公知的方式制得，通常包含至少一种活性化合物以及药学上可接受的稀释剂或载体。在制备本发明组合物时，活性成分通常与载体混合，或用载体稀释，和/或用例如胶囊、小药囊、纸或其它包容物形式的载体包裹。当载体起稀释剂作用时，它可以是固体、半固体或液体材料，它起活性成分的载体、赋形剂或介质的作用。因此，组合物可以是片剂、锭剂、小药囊、扁囊剂、酏剂、混悬液、固体或液体介质形式，含有例如不超过10%（重量）活性化合物的软膏、软和硬明胶囊、栓剂、注射溶剂和混悬液和灭菌粉剂。
适当载体的一些例子是乳糖、葡萄糖、蔗糖、山梨醇、甘露醇、淀粉、阿拉伯树胶、磷酸钙、藻朊酸盐、黄蓍胶、明胶、糖浆、甲基纤维素、羟基苯甲酸甲酯和丙酯、滑石粉、硬脂酸镁和矿物油。注射用组合物可按本领域公知的方法制成向病人给药后能快速、延缓或延迟释放活性成分的制剂。
当本发明化合物制成单位剂型时，它最好含5mg-500mg，例如10-200mg。“单位剂型”是指适于人和动物宿主单位剂量的物理上不连续的单元。每个单元包含所需的药用载体和予先计算好能产生期望的治疗效果量的活性物质。
活性化合物在很宽的剂量范围内都是有效的，例如日剂量通常为0.5-300mg/kg，更常用5-100mg/kg。但是，应当明白，用药量应由医师根据相应情况包括待治病性、给药选用的化合物及给药途径来确定，因此，上述剂量范围决无制定本发明范围之意。
下列实施例是对本发明的说明。
实施例1
将丙二腈（7.52g）和3，4-二甲氧基苯甲醛（18.95g）在乙醇（100ml）中的悬浮液搅拌下温热至回流温度。将桔色溶剂移离热源，从冷凝管上部加哌啶（0.5ml）。剧烈的反应一旦变缓，则再将反应混合物加热至回流温度，这样持续35分钟。这时出现大量亮黄色固体。将混合物在冰浴中冷却10分钟，滤出黄色固体，用乙醇和乙醚洗涤，于70℃真空干燥，得3，4-二甲氧基亚苄基丙二腈，m.p.137℃。
按类似方法制得下列化合物：
3-硝基亚苄基丙二腈，m.p.103℃
3-甲氧基亚苄基丙二腈，m.p.102℃
3-甲酯基亚苄基丙二腈，m.p.125℃
3-三氟甲基亚苄基丙二腈，m.p.81℃
3-二氯亚苄基丙二腈，m.p.154℃
实施例2
搅拌下，将哌啶（1.70g）滴加到5-羟基异喹啉（2.90g）和3，4-二甲氧基亚苄基丙二腈（4.28g）的乙醇（11ml）混悬液中。然后将混悬液加热回流一小时，得红色溶液。然后让它冷却至室温，有棕色固体析出。将其滤出，用乙醇和乙醚洗涤，于60℃真空干燥，得2-氨基-4-（3，4-二甲氧基苯基）-4H-吡喃并[2，3-f]异喹啉-3-甲腈黄棕色固体，m.p.225-228℃。
按类似方法制得下列化合物
2-氨基-4-（3，4-二氯苯基）-4H-吡喃并[2，3-f]异喹啉-3-甲腈，m.p.215-218℃。
2-氨基-4-（3-甲氧基苯基）-4H-吡喃并[2，3-f]异喹啉-3-甲腈，m.p.223-224℃。
2-氨基-4-（3-硝基苯基）-4H-吡喃并[2，3-f]异喹啉-3-甲腈，m.p.239-243℃。
2-氨基-4-（3-三氟甲基苯基）-4H-吡喃并[2，3-f]异喹啉-3-甲腈，m.p.117-118℃。
3-（2-氨基-3-氰基-4H-吡喃并[2，3-f]异喹啉-4-基）苯甲酸甲酯，m.p.229-230℃。
实施例3
搅拌下，用哌啶（1.70g）处理8-羟基喹啉（2.90g）和3，4-二甲氧基亚苄基丙二腈（4.28g）的乙醇（15ml）悬浮液中，室温下搅拌1小时。然后将混合物加热回流90分钟。然后让此红色溶液冷却至室温过夜。滤出沉淀的桔色固体，用乙醇和乙醚洗涤，于60℃真空干燥，得2-氨基-4-（3，4-二甲氧基苯基）-4H-吡喃并[3，2-h]喹啉-3-甲腈黄褐色固体，m.p.118-120℃。
按类似方法制得了下列化合物：
2-氨基-4-（3，4-二氯苯基）-4H-吡喃并[3，2-h]喹啉-3-甲腈，m.p.218-222℃。
2-氨基-4-（3-甲氧基苯基）-4H-吡喃并[3，2-h]喹啉-3-甲腈，m.p.190-192℃。
2-氨基-4-（3-硝基苯基）-4H-吡喃并[3，2-h]喹啉-3-甲腈，m.p.198-200℃。
2-氨基-4-（3-三氟甲基苯基）-4H-吡喃并[3，2-h]喹啉-3-甲腈，m.p.228-231℃。
3-（2-氨基-3-氰基-4H-吡喃并[3，2-h]喹啉-4-基）苯甲酸甲酯，m.p.208-210℃。
实施例4
搅拌下，用哌啶（410mg）处理5-羟基喹啉（703mg）和3-三氟甲基亚苄基丙二腈（1.07g）在乙醇（5ml）中的悬浮液。将此红色溶液于室温搅拌过夜，然后真空浓缩。残留物经合成硅酸镁层析，以二氯甲烷为洗脱剂，得188mg 2-氨基-4-（3-三氟甲基）-4H-吡喃并[2，3-f]喹啉-3-甲腈乳白色固体，m.p.167-168℃。
按类似方法制得了下列化合物：
2-氨基-4-（3，4-二氟苯基）-4H-吡喃并[2，3-f]喹啉-3-甲腈，m.p.223-228℃。
2-氨基-4-（3-甲氧基苯基）-4H-吡喃并[2，3-f]喹啉-3-甲腈，m.p.218-222℃。
2-氨基-4-（3-硝基苯基）-4H-吡喃并[2，3-f]喹啉-3-甲腈，m.p.200-202℃。
2-氨基-4-（3，4-二甲氧基苯基）-4H-吡喃并[2，3-f]喹啉-3-甲腈，m.p.160-163℃。
3-（2-氨基-3-氰基-4H-吡喃并[2，3-f]喹啉-4-基）苯甲酸甲酯，m.p.203-206℃。
实施例5
软明胶胶囊
每一粒软明胶胶囊包含：
活性成分 150mg
花生油 150mg
混合在一起后，用适当的设备将混合物装入软明胶胶囊。
实施例6
硬明胶胶囊
每一粒胶囊包含：
活性成分 50mg
PEG4000 250mg
将PEG4000烷化后与活性成分混合，在熔化状态下装入胶囊壳中，自然冷却。
实施例7
片剂
每片含10mg活性成分的片剂制备如下：
活性成分 10mg
淀粉 160mg
微晶纤维素 100mg
聚乙烯吡咯烷酮 13mg
（在水中的10%溶液）
羧甲基淀粉钠 14mg
硬脂酸镁 3mg
共计 300mg
将活性成分、淀粉和纤维素充分混合。向所得粉末中混入聚乙烯吡咯烷酮溶液，过筛。将制得的颗粒干燥后再过筛。然后向颗粒中加入羧甲基淀粉钠和硬脂酸镁，混合物用压片机压成重300mg的片剂。
实施例8
用大鼠脾细胞的伴刀豆球蛋白A反应作为本发明化合物活性的体外评估测定。文献中已描述了许多伴刀豆球蛋白A反应的测定方法。所用方法类似于P.Lacombe等人（FEBS3048191，227-230）所述的方法。我们在每个培养池中加2×105个细胞，伴刀豆球蛋白A的浓度为1μg/ml。必须加入2-巯基乙醇（2×10M-5），加入氚化胸苷0.25μCi，6小时后收集细胞。实施例1-4公开的全部化合物均能抑制细胞增生，在本试验中IC50均低于5μM。
Claims (8)
1、式(Ⅰ)化合物及其盐的制备方法：
R1是苯基或选自噻吩基、吡啶基、苯并噻吩基、喹啉基、苯并呋喃基或苯并咪唑基的杂芳基，所述苯基或杂芳基可带有取代基；或者R1是可被C1-4烷基取代的呋喃基；
R2是氰基、羧基、-COOR4(其中R4是酯基)、-CONR5R6(其中R5和R6各自是氢或C1-4烷基)或R7SO2-(其中R7是C1-4烷基或可被取代的苯基)，
R3是-NR8R9，-NHCOR8，-N(COR8)2，-N=CHOR8(其中R8和R9各自是氢或C1-4烷基)或-NHSO2R10(其中R10是C1-4烷基或可被取代的苯基)；或
式中X是C2-4亚烷基；基团
代表与苯并吡喃核稠合的吡啶环；
但如下定义的式(Ⅰ)化合物除外：其中
并且
(i)R1是苯基或在对位上被一个氯、羟基或甲氧基基团取代的苯基，
R2是氰基，且R3是-NH，
(ii)R1是苯基或在对位上被一个氯、羟基或甲氧基基团取代的苯基，R2是COOC2H5，且R3是-NH2，或者
(iii)R1是苯基，R2是氰基，且R3是-NHCOCH3或-N=CHOC2H5；
它包括：
(1)将式(Ⅵ)化合物
与式(Ⅶ)化合物
反应，得到R3是-NH2的式(Ⅰ)化合物；或者
(2)将式(Ⅷ)化合物
转化为R3是-NR8R9，NHCOR8，-N(COR8)2，-N=CHOR8，-NHSO2R10或
的式(Ⅰ)化合物。
2、按照权利要求1的方法，用来制备下式化合物：
3、按照权利要求1的方法，用来制备下式化合物：
4、权利要求1-3定义的任一化合物的制备方法，其中R′是可带有取代基的苯基。
5、权利要求1-4定义的任一化合物的制备方法，其中R2是氰基。
6、权利要求1-5定义的任一化合物的制备方法，其中R3是-NR8R9。
7、权利要求2定义的化合物的制备方法，其中R′是在间位上有一个取代基的苯基，R2是氰基且R3是-NH2。
8、药用组合物的制备方法，它包括将药用稀释剂或载体与式（Ⅰ）化合物或其药学上可接受的盐混合，式（Ⅰ）化合物如下：
R1是苯基或选自噻吩基、吡啶基、苯并噻吩基、喹啉基、苯并呋喃基或苯并咪唑基的杂芳基，所述苯基或杂芳基可带有取代基;或者R′是可被C1-4烷基取代的呋喃基;
R2是氰基、羧基、-COOR4（其中R4是酯基）、-CONR5R6（其中R5和R6各自是氢或C1-4烷基）或R7SO2-（其中R7是C1-4烷基或可被取代的苯基）;
R3是-NR8R9，-NHCOR8，-N（COR8）2，-N＝CHOR8（其中R8和R9各自是氢或C1-4烷基）或-NHSO2R10（其中R10是C1-4烷基或可被取代的苯基）;或
式中X是C2-4亚烷基;基团
代表与苯并吡喃核稠合的吡啶环。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9224169.4 | 1992-11-18 | ||
| GB929224169A GB9224169D0 (en) | 1992-11-18 | 1992-11-18 | Pharmaceutical compounds |
| GB9302367.9 | 1993-02-06 | ||
| GB939302367A GB9302367D0 (en) | 1993-02-06 | 1993-02-06 | Pharmaceutical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1092072A true CN1092072A (zh) | 1994-09-14 |
| CN1040982C CN1040982C (zh) | 1998-12-02 |
Family
ID=26301995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93115028A Expired - Fee Related CN1040982C (zh) | 1992-11-18 | 1993-11-17 | 吡喃并喹啉类及其盐的制备方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5434160A (zh) |
| EP (2) | EP1004584A3 (zh) |
| JP (1) | JPH06199862A (zh) |
| KR (1) | KR940011465A (zh) |
| CN (1) | CN1040982C (zh) |
| AU (1) | AU668602B2 (zh) |
| CA (1) | CA2103203A1 (zh) |
| CO (1) | CO4130335A1 (zh) |
| CZ (1) | CZ243493A3 (zh) |
| FI (1) | FI103727B1 (zh) |
| HU (1) | HU9303261D0 (zh) |
| IL (1) | IL107627A (zh) |
| NO (1) | NO304890B1 (zh) |
| NZ (1) | NZ250195A (zh) |
| PL (1) | PL301059A1 (zh) |
| TW (1) | TW289755B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115028643A (zh) * | 2022-06-10 | 2022-09-09 | 中国药科大学 | 吡喃并喹啉衍生物及其制备方法和应用 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9306062D0 (en) * | 1993-03-24 | 1993-05-12 | Lilly Industries Ltd | Pharmaceutical compounds |
| FR2795071B1 (fr) * | 1999-06-16 | 2001-07-27 | Adir | Nouveaux derives de carboxylate de 7-oxo-2,3,7,14- tetrahydro-1h-benzo[b]pyrano[3,2,h] acridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU781986B2 (en) | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2002092076A1 (en) | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| JP4593880B2 (ja) | 2001-05-16 | 2010-12-08 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された４ｈ−クロメンおよび類似体、並びにその使用方法 |
| US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| AU2003230411A1 (en) | 2002-05-16 | 2003-12-02 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo(2,3-h)chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP5031567B2 (ja) * | 2004-09-09 | 2012-09-19 | ハワード・フローレイ・インスティテュート・オブ・イクスペリメンタル・フィジオロジー・アンド・メディスン | 酵素阻害剤およびその使用 |
| US7843312B2 (en) * | 2006-12-12 | 2010-11-30 | Honeywell International Inc. | Wireless control of security system with key-operated key fob |
| NZ585338A (en) | 2007-11-19 | 2012-08-31 | Howard Florey Inst | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| CA2817331C (en) | 2010-11-12 | 2019-09-10 | Deutsches Krebsforschungszentrum (Dkfz) | Chromene derivatives and their analoga as wnt pathway antagonists |
| WO2023099589A1 (en) * | 2021-12-01 | 2023-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Irap inhibitors for use in the treatment of inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4243674A (en) * | 1978-06-12 | 1981-01-06 | Pfizer Inc. | 9-Hydroxydibenzo[b,d]pyrans and intermediates therefore |
| JPS61502124A (ja) * | 1984-05-09 | 1986-09-25 | ジ オ−ストラリアン ナシヨナル ユニヴア−シテイ− | 免疫応答の調節方法 |
| JP2631710B2 (ja) * | 1988-08-16 | 1997-07-16 | 日本ヘキスト・マリオン・ルセル株式会社 | ピラノ〔ｆ〕キノリノン誘導体及び該化合物を有効成分とする医薬組成物 |
| US4931221A (en) * | 1988-12-30 | 1990-06-05 | Ppg Industries, Inc. | Photochromic spiropyran compounds |
| US5284868A (en) * | 1991-10-09 | 1994-02-08 | Eli Lilly And Company | Pharmaceutical compounds |
| GB9306062D0 (en) * | 1993-03-24 | 1993-05-12 | Lilly Industries Ltd | Pharmaceutical compounds |
-
1993
- 1993-11-11 EP EP99204310A patent/EP1004584A3/en not_active Withdrawn
- 1993-11-11 EP EP19930308999 patent/EP0599514A3/en not_active Ceased
- 1993-11-12 US US08/150,945 patent/US5434160A/en not_active Expired - Fee Related
- 1993-11-15 PL PL93301059A patent/PL301059A1/xx unknown
- 1993-11-15 TW TW082109528A patent/TW289755B/zh active
- 1993-11-15 NZ NZ250195A patent/NZ250195A/en unknown
- 1993-11-15 AU AU50671/93A patent/AU668602B2/en not_active Ceased
- 1993-11-15 CZ CZ932434A patent/CZ243493A3/cs unknown
- 1993-11-16 IL IL107627A patent/IL107627A/xx not_active IP Right Cessation
- 1993-11-16 NO NO934145A patent/NO304890B1/no not_active IP Right Cessation
- 1993-11-16 KR KR1019930024262A patent/KR940011465A/ko not_active Application Discontinuation
- 1993-11-16 CA CA002103203A patent/CA2103203A1/en not_active Abandoned
- 1993-11-16 FI FI935065A patent/FI103727B1/fi active
- 1993-11-17 JP JP5287139A patent/JPH06199862A/ja active Pending
- 1993-11-17 CN CN93115028A patent/CN1040982C/zh not_active Expired - Fee Related
- 1993-11-17 CO CO93418738A patent/CO4130335A1/es unknown
- 1993-11-17 HU HU9303261A patent/HU9303261D0/hu unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115028643A (zh) * | 2022-06-10 | 2022-09-09 | 中国药科大学 | 吡喃并喹啉衍生物及其制备方法和应用 |
| CN115028643B (zh) * | 2022-06-10 | 2024-03-22 | 中国药科大学 | 吡喃并喹啉衍生物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0599514A3 (en) | 1994-07-06 |
| PL301059A1 (en) | 1994-05-30 |
| EP0599514A2 (en) | 1994-06-01 |
| CO4130335A1 (es) | 1995-02-13 |
| US5434160A (en) | 1995-07-18 |
| FI103727B (fi) | 1999-08-31 |
| NO934145L (no) | 1994-05-19 |
| JPH06199862A (ja) | 1994-07-19 |
| KR940011465A (ko) | 1994-06-21 |
| FI935065A (fi) | 1994-05-19 |
| CA2103203A1 (en) | 1994-05-19 |
| FI103727B1 (fi) | 1999-08-31 |
| IL107627A (en) | 1997-04-15 |
| CZ243493A3 (en) | 1994-06-15 |
| NO304890B1 (no) | 1999-03-01 |
| AU5067193A (en) | 1994-06-02 |
| NZ250195A (en) | 1995-12-21 |
| NO934145D0 (no) | 1993-11-16 |
| EP1004584A2 (en) | 2000-05-31 |
| HU9303261D0 (en) | 1994-03-28 |
| TW289755B (zh) | 1996-11-01 |
| FI935065A0 (fi) | 1993-11-16 |
| IL107627A0 (en) | 1994-02-27 |
| EP1004584A3 (en) | 2000-07-05 |
| CN1040982C (zh) | 1998-12-02 |
| AU668602B2 (en) | 1996-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1040982C (zh) | 吡喃并喹啉类及其盐的制备方法 | |
| CN1155589C (zh) | 调节雌激素受体的化合物 | |
| CN1034938C (zh) | 4H-萘并[1，2-b]吡喃化合物的制备方法 | |
| CN1064271A (zh) | 用于提高抗肿瘤活性的2，4-氨基喹唑啉的衍生物 | |
| CN1129102A (zh) | 用作肿瘤坏死因子释放抑制剂的儿茶酚二醚化合物 | |
| CN1075811C (zh) | 新型取代的2,4-噻唑烷二酮衍生物,其制备方法以及含有它们的药物组合物 | |
| CN1487925A (zh) | 三环内酰胺和磺内酰胺衍生物和它们作为组蛋白脱乙酰基转移酶抑制剂的应用 | |
| CN1319088A (zh) | 芳基磺酰基苯胺脲酶 | |
| CN1259131A (zh) | 化合物 | |
| CN1269811C (zh) | 具有sst1拮抗活性的哌嗪衍生物 | |
| CN1050128C (zh) | 5－酰胺基－1,2,4－噻二唑及其制备和药物组合物 | |
| CN1038680C (zh) | 二氢萘并[1，2-b]吡喃衍生物及其制备方法和用途 | |
| CN100436440C (zh) | 苯并吡喃酮化合物、其组合物以及其治疗方法 | |
| CN1254475C (zh) | 用作腺苷受体拮抗剂的5－甲氧基－8－芳基－[1,2,4]三唑并[1,5－a]吡啶衍生物 | |
| CN85105193A (zh) | 制备苯并噻吩止腹泻剂方法 | |
| CN1227538A (zh) | 含有4－氧代－丁酸的药物组合物 | |
| CN1063177C (zh) | 治疗偏头痛的吲哚烷基－吡啶基和嘧啶基哌嗪的1,2,5－噻二唑衍生物 | |
| CN1043527C (zh) | 制备胍衍生物的方法 | |
| CN1025857C (zh) | 制备具有药理性质的噻唑并[5，4-b][1，5]苯并二氮杂的方法 | |
| CN1028759C (zh) | 取代硫杂环烯并(3，2-b)吡啶的制备方法 | |
| CN1052117A (zh) | 免疫刺激性6-芳基-5，6-二氢咪唑并[2，1-b]噻唑衍生物的制备方法 | |
| CN1633421A (zh) | HPPAR－α受体的噁唑/噻唑衍生物活化剂 | |
| CN1168728C (zh) | 吡咯并异喹啉和四氢吡咯并异喹衍生物及其作为5-ht7受体介体的应用 | |
| CN1290829C (zh) | 制备环状硫代酰胺化合物的方法 | |
| CN1524850A (zh) | 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |